Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001641172-25-002606
Filing Date
2025-04-03
Accepted
2025-04-03 17:17:38
Documents
20
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 formpre14a.htm   iXBRL PRE 14A 696565
2 pre14a_001.jpg GRAPHIC 38906
3 pre14a_002.jpg GRAPHIC 37472
4 pre14a_004.jpg GRAPHIC 28349
5 proxy_001.jpg GRAPHIC 954588
6 proxy_002.jpg GRAPHIC 509709
  Complete submission text file 0001641172-25-002606.txt   5064014

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE erna-20241231.xsd EX-101.SCH 6167
8 XBRL DEFINITION FILE erna-20241231_def.xml EX-101.DEF 10690
9 XBRL LABEL FILE erna-20241231_lab.xml EX-101.LAB 65718
10 XBRL PRESENTATION FILE erna-20241231_pre.xml EX-101.PRE 45362
22 EXTRACTED XBRL INSTANCE DOCUMENT formpre14a_htm.xml XML 160975
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-11460 | Film No.: 25810742
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)